Literature DB >> 15147040

Ex vivo enhancement of antigen-presenting function of dendritic cells and its application for DC-based immunotherapy.

Mie Nieda1, Mai Tomiyama, Kohji Egawa.   

Abstract

Dendritic cells (DCs) are potent antigen presenting cells that are able to initiate and modulate immune responses and are hence exploited as cellular vaccines for immunotherapy. In particular DCs generated from peripheral blood monocytes (Mo-DCs) have been used with promising results as a new approach for the immunotherapy of cancer. In this study, we have analyzed the changes in the pattern of expression molecules on Mo-DCs during DC maturation using different maturation cytokine combinations and the expansion capacity of an antigen specific CD8+T cells monitored by flow cytometry with the fluorescent tetramers and anti-CD8 monoclonal antibody. These analyses revealed that the expansion of antigen specific CD8+T cells is the most effective when T cells were activated by fully maturated DCs by culturing monocytes for 5 days in the presence of GM-CSF and IL-4, followed by 2-3 days of maturation with pro-inflammatory mediators including TNFalpha, IL-6, IL-1beta and PGE2. These results pave the way to a more effective immunotherapy using DCs for patients with malignancy, as well as infectious diseases.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15147040     DOI: 10.1111/j.1749-0774.2003.tb00154.x

Source DB:  PubMed          Journal:  Hum Cell        ISSN: 0914-7470            Impact factor:   4.174


  19 in total

1.  CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells.

Authors:  L J Zhou; T F Tedder
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-19       Impact factor: 11.205

Review 2.  Origin, maturation and antigen presenting function of dendritic cells.

Authors:  M Cella; F Sallusto; A Lanzavecchia
Journal:  Curr Opin Immunol       Date:  1997-02       Impact factor: 7.486

3.  Dendritic cells hold promise for immunotherapy.

Authors:  G Girolomoni; P Ricciardi-Castagnoli
Journal:  Immunol Today       Date:  1997-03

4.  Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues.

Authors:  D Valmori; J F Fonteneau; C M Lizana; N Gervois; D Liénard; D Rimoldi; V Jongeneel; F Jotereau; J C Cerottini; P Romero
Journal:  J Immunol       Date:  1998-02-15       Impact factor: 5.422

5.  Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease.

Authors:  R Khanna; S Bell; M Sherritt; A Galbraith; S R Burrows; L Rafter; B Clarke; R Slaughter; M C Falk; J Douglass; T Williams; S L Elliott; D J Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-31       Impact factor: 11.205

6.  Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation.

Authors:  F Sallusto; P Schaerli; P Loetscher; C Schaniel; D Lenig; C R Mackay; S Qin; A Lanzavecchia
Journal:  Eur J Immunol       Date:  1998-09       Impact factor: 5.532

7.  Macrophage inflammatory protein 3alpha is involved in the constitutive trafficking of epidermal langerhans cells.

Authors:  A S Charbonnier; N Kohrgruber; E Kriehuber; G Stingl; A Rot; D Maurer
Journal:  J Exp Med       Date:  1999-12-20       Impact factor: 14.307

8.  CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF+TNF alpha.

Authors:  C Caux; B Vanbervliet; C Massacrier; C Dezutter-Dambuyant; B de Saint-Vis; C Jacquet; K Yoneda; S Imamura; D Schmitt; J Banchereau
Journal:  J Exp Med       Date:  1996-08-01       Impact factor: 14.307

9.  Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha.

Authors:  F Sallusto; A Lanzavecchia
Journal:  J Exp Med       Date:  1994-04-01       Impact factor: 14.307

10.  Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes.

Authors:  P Romero; P R Dunbar; D Valmori; M Pittet; G S Ogg; D Rimoldi; J L Chen; D Liénard; J C Cerottini; V Cerundolo
Journal:  J Exp Med       Date:  1998-11-02       Impact factor: 14.307

View more
  2 in total

1.  Novel innate immune functions for galectin-1: galectin-1 inhibits cell fusion by Nipah virus envelope glycoproteins and augments dendritic cell secretion of proinflammatory cytokines.

Authors:  Ernest L Levroney; Hector C Aguilar; Jennifer A Fulcher; Luciana Kohatsu; Karen E Pace; Mabel Pang; Kevin B Gurney; Linda G Baum; Benhur Lee
Journal:  J Immunol       Date:  2005-07-01       Impact factor: 5.422

2.  The Basics of Artificial Antigen Presenting Cells in T Cell-Based Cancer Immunotherapies.

Authors:  Lillian R Neal; Stefanie R Bailey; Megan M Wyatt; Jacob S Bowers; Kinga Majchrzak; Michelle H Nelson; Carl Haupt; Chrystal M Paulos; Juan C Varela
Journal:  J Immunol Res Ther       Date:  2017-06-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.